A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy
Phase of Trial: Phase III
Latest Information Update: 30 Dec 2014
At a glance
- Drugs Mitiglinide (Primary) ; Biguanides; CD26 antigen inhibitors
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Kissei Pharmaceutical
- 10 Jun 2017 Biomarkers information updated
- 30 Nov 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
- 01 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.